logo
  

Bayer's Finerenone Meets Primary Endpoint In Phase III Cardiovascular Study

Bayer's (BAYZF.PK,BAYRY.PK,BYR.L) phase III study FIGARO-DKD, which evaluated the efficacy and safety of the investigational drug finerenone versus placebo when added to standard of care in patients with chronic kidney disease or CKD and type 2 diabetes or T2D, has met its primary endpoint.

The study results showed that finerenone significantly reduced the composite risk of time to first occurrence of cardiovascular or CV death or non-fatal CV events (myocardial infarction, stroke, or heart failure hospitalization).

Compared to FIDELIO-DKD, the first of the two Phase III studies investigating finerenone in patients with CKD and T2D, FIGARO-DKD included more patients with earlier stage CKD and T2D.

FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven Phase III study investigating finerenone versus placebo in patients with CKD and T2D. The study included approximately 7,400 patients from more than 1,000 sites across 47 countries worldwide.

Patients were randomized to receive either finerenone 10 mg or 20 mg orally once daily or placebo when added to standard of care, including blood glucose lowering therapies and maximum tolerated dose of RAS-blocking therapy such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs).

Bayer also recently announced the initiation of the FINEARTS-HF study, a multicenter, randomized, double-blind, placebo-controlled Phase III study which will investigate finerenone compared to placebo in more than 5,500 patients with symptomatic heart failure with a left ventricular ejection fraction of =40%.

The primary objective of the study is to demonstrate superiority of finerenone over placebo in reducing the rate of the composite endpoint of cardiovascular death and total heart failure events.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google has revoked its three-year ban on cryptocurrency-related ads on its sites under the search giants' new ad services policy. This action will now allow cryptocurrency exchanges and wallets certified by Google to advertise their products and services on Google's network, beginning August 3, 2021. The UK's competition regulator said Friday that it has secured commitments from Google to address concerns about the tech giant's proposal to remove third-party cookies from Chrome browser. Archer Aviation, a developer of electric vertical take-off and landing or eVTOL aircraft, unveiled its autonomous electric two-seater aircraft, named "Maker", marking a milestone towards its commercial launch. The California-based air mobility company, which has already received orders from United Airlines, will use its inaugural aircraft prototype for testing as it works towards certification.
Follow RTT